白蛋白结合型紫杉醇治疗晚期复发乳腺癌的近期疗效OA

Objective To explore the short-term efficacy of albumin-bound paclitaxel in the treatment of advanced recurrent breast cancer.Methods A total of 100 patients with advanced recurrent breast cancer who received treatment at the 967 Hospital of the Joint Logistic Support Force of the Chinese People's Liberation Army from March 2022 to March 2023 were selected as the study objects,and were randomly divided into control group and observation group,with 50 cases in each group.The control group was treated with paclitaxel injection,and the observation group was treated with albumin-bound paclitaxel.The level of tumor markers,immune function before and after treatment,efficacy and incidence of adverse drug reactions were compared between the two groups.Results The levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and carbohydrate antigen 135(CA135)in observation group were lower than those in control group(P＜0.05).After treatment,the levels of CD3+,CD4+,CD8+and CD4+/CD8+in the observation group were better than those in the control group(P＜0.05).The effective rate of the observation group was higher than that of the control group(P＜0.05).The incidence of adverse reactions in observation group was lower than that in control group(P＜0.05).Conclusion The use of albumin-bound paclitaxel in the treatment of advanced recurrent breast cancer can effectively reduce the level of tumor markers and the toxic side effects of drugs,optimize immune function,improve clinical therapeutic effect,and have significant clinical application value.